SCHEMBL6793771

SCHEMBL6793771

COC1=C(C(=O)NCCCN(C)C)N(C)S(=O)(=O)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 1/20 0.53
POLB P06746 2/20 0.44
DRD2 P14416 1/20 0.43
HSD11B1 P28845 2/20 0.43
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
KCNA3 P22001 1/20 0.41
ALOX15 P16050 2/20 0.41
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 2/20 0.40
LMNA P02545 2/20 0.40
THRB P10828 2/20 0.40
MCHR1 Q99705 1/20 0.40
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
NFKB1 P19838 1/20 0.40
PTGS1 P23219 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propoxicam SCHEMBL29685544 0.87 PTGS1 (0.54) HSD11B1ALOX15KDM4ECYP1A2LMNA
SCHEMBL7087940 0.85 CAPN1 (0.53) CAPN1POLBHSD11B1TP53MAPT
Iodide SCHEMBL6796588 0.84 CAPN1 (0.52) CAPN1POLBHSD11B1TP53MAPT
SCHEMBL6797405 0.83 PTGS1 (0.53) HSD11B1ALOX15KDM4ECYP1A2LMNA
SCHEMBL6803658 0.76 HSD11B1 (0.54) HSD11B1ALOX15KDM4ECYP1A2LMNA
SCHEMBL6797674 0.76 PTGS1 (0.57) HSD11B1ALOX15KDM4ECYP1A2LMNA
SCHEMBL6794794 0.76 CAPN1 (0.57) CAPN1POLBHSD11B1TP53MAPT
SCHEMBL7088707 0.76 CAPN1 (0.59) CAPN1POLBHSD11B1TP53MAPT
SCHEMBL13243354 0.76 CAPN1 (0.60) CAPN1POLBHSD11B1MAPTALOX15
SCHEMBL7175203 0.74 MAPT (0.48) CAPN1POLBHSD11B1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063696-A1 1,1-dioxo-2h-1,2-benzothiazine-3-carboxamide derivatives,method for preparing same and pharmaceutical compositions comprising same INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2004-04-01 US disclosed
EP-1343774-A1 1,1-DIOXO-2H-1, 2-BENZOTHIAZINE-3-CARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Les Laboratoires Servier (FR) 2003-09-17 EP disclosed
WO-2002050049-A1 1,1-DIOXO-2H-1, 2-BENZOTHIAZINE-3-CARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME LES LABORATOIRES SERVIER (FR) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063696-A1 1,1-dioxo-2h-1,2-benzothiazine-3-carboxamide derivatives,method for preparing same and pharmaceutical compositions comprising same ADCY2, ADCY1, HRH2 CAPN1 2480/4885POLB 4037/4885DRD2 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.